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STUDIES ON THE CONTACT SENSITIZATION OF MAN WITH 
SIMPLE CHEMICALS 
ITI. Quantitative Relationships Between Specific Lymphocyte Transformation, Skin Sensitivity, and 
Lymphokine Activity in Response to Dinitrocblorobenzene 
WILLIAM R LE\'IS, M.D., JOHN J. WHALEN, M.S., AND JOHN A. POWELL, M.D. 
Dermatology Branch, National Cancer Institute, Bethesda, Maryland 
Dinitrochlorobenzene (DNCB) coupled to peripheral blood erythrocytes or leukocytes 
forms a particulate complex, DNCB-antigen. The addition of DNCB-antigen induced 
blastogenesis and DNA synthesis in leukocyte cultures from DNCB-sensitized human 
subjects and not in leukocyte cultures from nonsensitized controls. In general, 
sensitized subjects who displayed a higher degree of cutaneous reactivity to DNCB, as 
manifested by duration and intensity of dermatitits, also showed a greater blastogenic 
response to DNCB-antigen in vitro. This quantitative correlation, however, was not 
invariant. Certain soluble factor{s), or lymphokines are released following the addition of 
DNCB-antigen to leukocyte cultures prepared from some sensitive subjects who were 
rechallenged one or more times with DNCB. These lymphokines induce blastogenesis in 
secondary target leukocyte populations from non sensitized subjects. Extended studies are 
presented which show little or no lymphokine activity in peripheral blood leukocyte cultures 
during a primary immune response, despite high degrees of blastogenic activity in response to 
DNCB-antigen. Significant Iymphokine activity was observed only following additional 
rechallenge with DNCB. 
Blastogenesis and skin reactivity specific for DNCB have been shown to develop at about 
the same time during a primary immune response. This, along with the quantitative 
correlation shown in this communication, suggests that both processes probably reflect 
thymic-dependent cellular immunity. The appearance of lymphokine activity following 
rechallenge with DNCB suggests that DNCB-induced Iymphokines may represent an 
amplifying mechanism of the cellular immune response that involves recruitment of 
previously uncommitted lymphocytes. 
Allergic contact dermatitis to dinitrochloroben-
zene is generally accepted as a manifestation of 
cell-mediated immunity (CMD [1,2J_ Lymphocyte 
transformation has also been reported as a fre-
quent in vitro correlate or manifestation of CMI 
[3,51. We have previously reported a specific blas-
togenic response to DNCB complexed to leuko-
cytes [6J or erythrocytes [7J. These ONCB com-
plexes are referred to as DNCB-antigen and induce 
blastogenesis and ONA synthesis only in leukocyte 
cultures from ONCB-sensitized subjects. Exten-
sions of these studies indicate that lymphokine(s) 
is specifically induced in sensitive leukocyte 
cultures by DNCB-antigen [8J. These DNCB-
induced lymphokines are unrelated to 
histocompatibility factors and induce similar de-
grees of blastogenesis in autologous-sensitive and 
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allogeneic and syngeneic leukocyte cultures from 
nonsensitized subjects [9J. The blastogenic activ-
ity therefore appears similar to cell-free soluble 
factors referred to as "lymphokines" which have 
been implicated as possible mediators of cellular 
immunity [10J. 
In previous studies we bave presented over 30 
experiments in which nonsensitized subjects 
showed no significant response to ONCB-antigen 
while, simultaneously, sensitized subjects showed 
from 4- to over 100-fold increases in DNA synthesis 
[6,7]. In this report we illustrate a quantitative 
relationship between the intensity and duration of 
cutaneous inflammation to DNCB in vivo, and 
lymphocyte transformation to ONCB-antigen in 
vitro. In addition, little or no Iymphokine activity 
was observed in 12 subjects studied following a 
primary sensitization with DNCB even with high 
levels of blastogenesis to ONCB-antigen. Only 
after additional rechallenge with DNCB was signif-
icant lymphokine activity observed. 
Since specific blastogenesis and skin reactivity 
to DNCB convert at about the same time during a 
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primary immune response and show a quantitative 
relationship, it seems probable that both are a 
reflection of thymic-dependent cellular immunity. 
Lymphokine activity, manifested by cell-free solu-
ble blastogenic factor(s) released in DNCB-anti-
gen-stim ulated sensitive leukocyte cultures, may 
represent an amplifying mechanism of the cellular 
immune response involving recruitment of previ-
ously uncommitted lymphocytes. 
MATERIALS AND METHODS 
Sensitization and patch testing with DNCB. A sensi-
tiziog dose of 2,000 I'g of DNCB in 0.1 ml of acetone was 
applied to the skin of the medial aspect of both upper 
arms within a 2-cm diameter polyethylene ring, allowed 
to evaporate, and covered by an adhesive bandage for 2 
days. Simultaneously 50 "g and 5 "g of DNCB in acetone 
were applied to one forearm [2,7]. On days 3, 6, and 9 
following application of the sensitizing dose, subjects 
were challenged with 200 ltg, 10 ltg, and 11'g of DNCB in 
a cream base [Acid Mantle Creme (aluminum acetate). 
Dome Laboratories. Westhaven, Conn.] under partial 
occlusion (Johnson & Johnson Sheer patches) for 2 
days. 
Subjects and recording of cutaneous reactivity to 
DNCB. Healthy adult volunteers were sensitized in the 
above manner and cutaneous reactivity to DNCB was 
recorded daily at each of the patch-test sites. Erythema 
alone was recorded as 1 +. erythema and induration as 
2 +, vesicle formation as 3 +. 
Preparation of DNCB-antigen. We have previously 
described in detail the preparation of DNCB complexes 
used for in vitro stimulation. These complexes can be 
prepared with leukocytes [6 J or erythrocytes [7 J and form 
nontoxic. storable. particulate complexes referred to as 
DNCB-antigen. In the current study all DNCB-antigen 
used was prepared with erythrocytes from a type O-posi-
tive donor. Briefly. 3 ml of packed erythrocytes was 
suspended in 40 ml of undiluted DMSO (dimethyl 
sulfoxide, Aldrich Chemical Co., Inc. Milwaukee, Wis-
consin) containing 1 gm/100 ml of DNCB (l-ohloro-2,4-
dinitrobenzene. Eastman Kodak Organic Chemicals 
Div., Eastman Kodak Co., Rochester, N. Y.J. After I-hr 
incubation at 38'C the cell pellet was washed once with 
DMSO, and twice with Medium 199, lyophilized, and 
stored in the dark at 4 'C. 
Preparation of leukocyte cultures and addition of 
DNCB-antigen. "Mononuclear leukocyte culture fluid" 
was prepared by diluting the "mononuclear leukocyte-
rich plasma" obtained by centrifugation [11 J with 4 parts 
of tissue culture medium (RPM! 1640 Grand Island 
Biological. 1876) containing penicillin and streptomycin. 
This method yields a final concentration of 0.4-2 x 10' 
cells/ml of which 70-90% are lymphocytes [11]. 
Lyophilized DNCB-antigen prepared from erythro-
cytes as above was suspended in "cell-free" culture 
fluid" (20% plasma in RPMI 1640) at a concentration of 
250 I'g/ml and mixed 1:9 with mononuclear leukocyte 
culture fluid to give a final concentration of 25 I'g 
DNCB-antigen per ml of culture. An equal volume of 
cell-free culture fluid without DNCB-antigen was added 
to unstimulated control cultures. The plasma was the 
same for all stimulated and unstimulated cultures within 
each experiment. All cultures were cultured in 0.5-ml 
volumes at 38"C with room air as the gas phase in 12 x 35 
mm screw·capped vials (Arthur H. Thomas Co., Phila-
delphia, Pa.). 
Lymphokine supernate harvest and assay. Details of 
this procedure are published elsewhere [BJ In brief, 
cultures for the production of Iymphokine(s) were pre-
pared by culturing leukocytes alone (unstimulated con-
trol cultures) or in the presence of DNCB-antigen 
(DNCB-antigen stimulated cultures). These primary 
cultures were obtained during the third week following 
sensitization or rechallenge with DNCB. Detailed studies 
of the kinetics of Iymphokine production have shuwn this 
to be an appropriate time to measure lymphokine activ-
ity (manuscript in preparation). These cells were cul-
tured in 5-ml volumes at 38"C with room air as the gas 
phase in 2-oz prescription flasks. In studies presented in 
this report. supernates from these cultures were har-
vested by centrifugation between 46 to 51 hr and were 
filtered through 0.45-1' Millipore filters; 0.5-ml aliquots of 
the primary cultures were removed at the time of 
supernate harvest, placed in 12 x 35 mm screw-capped 
vials (Arthur H. Thomas Co.), and assayed for DNA 
synthesis. Assay of Iymphokine activity involved the 
addition of supernates of stimulated and unstimulated 
primary cultures to secondary leukocyte cultures pre-
pared from DNCB-insensitive subjects. The concentra-
tion of leukocytes was maintained constant within each 
experiment. Secondary target leukocyte cultures were 
cultured in 0.5-ml volumes at 38"C with room air as the 
gas phase in 12 x 35 mm screw-capped vials. 
Evaluation of cultures. Tritiated thymidine incorpora-
tion during DNA synthesis was measured between the 
115th and 125th hr. In each experiment, duplicate or 
triplicate cultures were assayed at the same time and the 
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FIGURE. Correlation between DNCB skin sensitivity in 
vivo and specific lymphocyte transformation in vitro. 
'In vitro lymphocyte transformation in leukocyte 
cultures prepared from 10 subject's 20 days following 
application of a primary sensitizing dose of DNCB. Plot 
represents rank order from 1 to 10 of stimulation ratios 
DNCB-antigen-stimulated (cpm) 
unstimulated control (cpm) 
'In vivo skin test reactivity of these 10 subjects on day 
20 following application of a primary sensitizing dose of 
DNCR Plot represents rank order of intensity of dilu· 
tional patch test applied On day 6. 
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TABLE I. Detailed tabulation in vitro and in vivo data on 10 DNCB-sensitized subjects 
In vitro culture reactivity-ll 
In vivo skin reactivityb 
Subjects DNA synthesis in CPM Ratio 
Unstimulated control DNCB-Ag·stimulated Stimulatedlcontrol Rank 200~g lO~g Rank 
T.J. 362 ± 166 11233 ± 385 3l.0 I 10 2+ 2+ 9 A.L. 281 ± 11 8384 28.9 9 
I 
0 0 1 
8.S. 3445 ± 1073 77089 ± 1719 22.4 I 8 2+ 2+ 9 
W.B. 897 ± 421 7624 ± 638 : 8.5 7 2+ 1+ 6.5 
D.T. 994 ± 418 6591 ± 132 6.6 6 2+ 2+ 9 
T.A. 480 ± 26 2727 ± 279 5.7 5 2+ 0 4.5 
R.F. 489 ± 7 2308 ± 154 4.7 4 2+ 1+ 6.5 
I 
J.D. 4910 
I 
10251 ± 763 2.1 3 2+ 0 4.5 
R.C. 
I 
643 ± 95 907 ± 363 1.4 2 1+ 0 2.5 
E.A. 199 ± 9 219 ± 9 i 1.1 1 1+ 0 2.5 
a Leukocyte cultures prepared on day 20 following application of a primary sensitizing dose of DNCB. 
• Intensity of skin response 20 days following application of a primary sensitizing dose of DNCB to dilutionsl patch 
tests ofDNCB applied on day6. In vivo skin reactivity rank is based on the sum of reactivities of the patch tests. When 
two or three subjects manifested the same degree of skin reactivity. a mean of the rank values was assigned (e.g., 
subjects R.C. and E.A. were the 2nd and 3rd least reactive and were eacb assigned a value of 2.5). 
results expressed as the mean counts per minute (± 8E) 
of replicate cultures. The assay system uses a 3-hr 
incubation with [metbyl-'H I thymidine and a Millipore 
filter collection technique (Millipore Corp., Bedford, 
Mass.) tbat has been described elsewhere [12,13]. 
RESULTS 
In general, subjects who displayed a higher 
degree of cutaneous reactivity to DNCB, as mani-
fested by duration and intensity of dermatitis, 
showed a greater blastogenic response to 
DNCB-antigen in vitro. The Figure shows the rank 
order plot of in vivo skin test reactivity versus the 
in vitro blastogenic response to DNCB-antigen in 
10 DNCB-sensitized subjects. One subject dis-
played a disproportionately high degree of in vitro 
blastogenesis to DNCB-antigen compared to his 
low degree of skin test reactivity. Table I shows in 
greater detail the in vitro and in vivo results from 
these sensitized subjects. 
Two subjects (RC. and E.A.) who showed very 
little skin reactivity also failed to show significant 
blastogenesis in response to DNCB-antigen. Previ-
ous studies from our laboratory on over 30 subjects 
have shown a similar lack of response in nonsensi-
tized individuals [7]. While subject J.D. has a 
stimulation ratio of only 2.1, he could be distin-
guished from nonsensitized controls on the basis of 
net counts per minute at this time. Furthermore, 
all 3 of these subjects showed significant blas-
togenesis to DNCB-antigen following subsequent 
rechallenge with DNCB. 
These 10 subjects as well as 2 additional DNCB-
sensitized subjects were studied for lymphokine 
production following a primary sensitization with 
DNCB, and 7 of these 12 were also studied follow-
ing additional rechallenges with DNCB. Very little 
or no lymphokine activity was detected in any of 
the 12 subjects during a primary sensitization 
(Table II, column 1 and footnote c). However, 
significant levels were detected in 2 of 6 subjects 
studied after one rechallenge with DNCB (Table 
II, column 2) and 4 of 7 subjects studied after a 
second rechallenge (Table II, column 3). All but 
2 of the 12 subjects, who failed to show significant 
lymphokine activity following a primary sensitiza-
tion with DNCB, showed good blastogenic activity 
to DNCB-antigen with one response in excess of 
70,000 cpm (Table I). After the first and second 
rechallenge, all su bjects showed a good blastogenic 
response to DNCB-antigen. Thus, even in the face 
of a good blastogenic response in primary cultures, 
lymphokine activity could be detected only after 
one or more rechallenges with DNCB. 
DISCL'SSION 
Our results indicate a quantitative correlation 
between the intensity and duration of skin tests 
with topical DNCB in vivo and the degree of 
lymphocyte transformation induced by DNCB-an-
tigen in vitro. The correlation was not invariant. 
One subject with a very low degree of in vivo skin 
test reactivity showed a high degree of lymphocyte 
transformation in vitro. The lack of perfect correla-
tion might be explained by difficulties in accu-
rately quantifying and comparing responses of the 
in vitro system and/or by difficulties in accurately 
comparing quantitative in vivo patch-testing re-
sults. Alternatively, the occasional disociation may 
indicate that the in vitro response reflects an 
earlier or different portion of the immune response 
than the in vivo skin test. We have previously 
demonstrated a temporal association between 
onset of skin reactivity to DNCB and onset of 
specific in vitro blastogenesis to DNCB-antigen 
during a primary immune response [6,7]. This, 
along with the quantitative correlation illustrated 
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in this paper, suggests that the in vitro blastogenic 
response to DNCB-antigen, like the skin test, is 
also a reflection of thymus·dependent eMI. The 
occasional dissociation, if not due to technical 
failure, may reflect the measurement of an earlier 
or different area of thymus-dependent immunity or 
possibly a measure of two different antigenic 
determinants, e.g., DNP·skin protein and DNp· 
erythrocyte protein. 
The discovery of Iymphokine(s) in allergic con-
tact dermatitis to DNCB further suggests that the 
in vitro blastogenic response to DNCB-antigen is a 
manifestation of cellular immunity. Dumonde et al 
[lOJ suggested the term Iymphokine to describe 
"non-antibody mediators of cellular immunity 
generated by lymphocyte activation." The demon-
stration of lymphokine activity in response to PPD 
[10J, Concanavalin A[14], mixed leukocyte activ-
ity [15], and in allergic contact sensitivity to DNCB 
[8,9] certainly suggests a relationship of these 
factors to cell-mediated immunity. While some 
qualitative differences may exist between the vari-
ous mediators responsible for tuberculin type hy· 
persensitivity, allograft rejection, and allergic con-
T ABLE II. Initiation of lymphokine production following DNCB rechallenge 
Subject 
T.J. 
A.L. 
D.T. 
RF. 
J.D. 
RC. 
B.M. 
Thymidine incorporation 
Unstimulated 
Stimulated 
Lymphokine 
activity'/) 
Unstimulated 
Stimulated 
Lymphokine 
activity 
Unstimulated 
Stimulated 
Lymphokine 
activity 
Unstimulated 
Stimulated 
Lymphokine 
activity 
Unstimulated 
Stimulated 
Lymphokine 
activity 
Unstimulated 
Stimulated 
Lymphokine 
activity 
Unstimulated 
Stimulated 
Lymphokine 
activity 
Average lymphokine activity 
Primary s-ensitization 
769 ± 509 I 
1416 ~ 290 
647 
268 
1042 
774 
687 ± 145 
854 I 288 
167 
1447 ~ 7:35 
1332 
-125 
650 ± 8 
2070 ± 300 
142{) 
375 I 25 
1076 ± 186 
701 
128 = 38 
402 ± 31 
274 
551" 
Filst rechallengeoQ Second rechallenge"-
669 ± 489 270 ± 39 
10364 I 6573 12512 ± 1608 
19695/ , 122421 
156 ± 26 353 ± 1 
618 ± 188 4324 ± 414 
462 /39711 
1007 ± 426 518 ± 64 
969 I 674 576 I 130 
-38 58 
689 I 256 305 ± 49 
1109 ± 84 1006 ± 48 
412 701 
758 ± 70 158, ± 417 
3020 I 258 23500 ~ 454 
12262/ 1219191 
776 ± 162 196 ± 12 
1061 ± 153 266 ± 12 
285 70 
191 ± 18 
Blood not drawn 3082 ± 12 
128911 
121801 /597@ 
a Subjects were rechallenged with DNCB patch test 2 months (lst rechallenge) and 5 months (2nd rechallenge) after 
the primary sensitizing application of DNCB. 
• Primary cultures for lymphokine production were prepared from leukocytes obtained during the third week 
following sensitization or rechallenge. Supernatants from these primary cultures were harvested after 48 hr of culture; 
unstimulated and stimulated supernatants constituted 90% of the secondary "insensitive" leukocyte cultures by 
volume. Lymphokine activity ~ cpm in secondary stimulated-unstimulated cultures. 
'Five additional subjects, not included in this table, were studied during a primary sensitization in the same 
manner. Average lymphokine activity for these 5 subjects was 504 cpm, thus being similar to the 7 subjects shown 
above. 
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tact dermatitis, each of these forms of cellular 
immunity exhibits similar blastogenic Iymphokine 
activity in vitro. The ability to control exposure 
and thus the degree of sensitivity [16,17] to the 
primary immunogen, DNCB, has allowed us to 
discover the absence of significant Iymphokine 
production during a primary immune response and 
its appearance following subsequent rechallenge 
with DNCB in humans. While not all subjects 
show detectable Iymphokine activity, even with 
high levels of blastogenesis to DNCB-antigen, 
those who demonstrate this activity have been 
challenged one or more times or have been re-
ceiving topical DNCB over an extended period of 
time as part of an immunotherapy protocol [8]. 
The in vivo biologic significance of these in vitro 
defined substances remains speculative. However, 
the ability of Iymphokine(sl to activate lympho-
cytes from nonsensitized subjects and the absence 
of significant Iymphokine production during a 
primary immune response suggests the possibility 
that these substances may represent a mechanism 
for amplifying the cellular immune response by 
recruiting previously uncommitted lymphocytes in 
sensitized subjects undergoing repeated challenge 
with DNCB. While conclusions on the role of these 
in vitro defined substances requires further charac-
terization, isolation, and study in both animal 
and human systems, contact sensitivity with 
DNCB offers a versatile and ethically feasible 
system for elucidating the in vivo role of lympho-
kines in humans. 
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